3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
2
Lymphatic Abnormalities
2
Lymphangioma, Cystic
2
Lymphangioma
2
Vascular Malformations
1
Solid Tumor
1
Skin Diseases, Vascular
1
Ovarian Neoplasms
1
Neoplasms
1
Meningioma
1
Melanoma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Arteriovenous Malformations
1
Interventions
Alpelisib
2
mirdametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphatic Abnormalities
×
Alpelisib
×
Clear all
NCT05948943
2026-05-12
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled
NCT05983159
2026-05-05
TARGET-VM
Murdoch Childrens Research Institute
Phase 2
Recruiting
50 enrolled